HomeSite MapContact Us

Company

Collaborations

Partnering Opportunities

Selecta  Biosciences is actively seeking collaborations including in-licensing and out-licensing opportunities that would be consistent with its product and business strategy. Out-licensing and research collaboration opportunities exist for Selecta Biosciences' Synthetic Vaccine Particle (SVP) programs. Areas of interest include autoimmune diseases, allergies and marketed biologics. Selecta Biosciences is also looking for in-licensing opportunities to maintain, advance and fortify its proprietary position in its SVP-based immunotherapy program and product candidates.

Collaborations


Sanofi logo

Sanofi and Selecta Biosciences are collaborating to research novel SVP products for the treatment of a life-threatening food allergy, celiac disease and type 1 diabetes.
Click here to learn more about the 2012 license for severe food allergies

Click here to learn more about the 2015 addition of celiac disease

JDRF_2C_Logo


Together with Sanofi, Selecta Biosciences and The Juvenile Diabetes Research Foundation (JDRF) are collaborating to research SVP formulations for the treatment of type 1 diabetes, an autoimmune disorder. In September 2014 JDRF and Sanofi awarded a grant to Selecta Biosciences in furtherance of this program.
Click here to learn more about the 2011 collaboration

Click here to learn more about the 2014 extension of the collaboration

 

Genethon

Genethon and Selecta Biosciences joined forces in 2015 to co-develop an adeno-associated virus (AAV)-based gene therapy designed to mitigate the formation of anti-drug antibodies to enable repeat administration.Click here to learn more
 

NIDA1

In 2014, Selecta  Biosciences was awarded a $8.1 million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH), to support research into the development of a next generation vaccine for smoking cessation and relapse prevention.


bmgf

In 2013, Selecta Biosciences was awarded a $1.2 million grant from the Bill and Melinda Gates Foundation to fund the Company’s immune stimulation program for a prophylactic malaria vaccine


Skolkovo2

The Skolkovo foundation is providing non-dilutive funding to support Selecta Biosciences’s development of its SVP program designed to treat human papilloma virus-associated cancers by stimulating the immune system.

Read more here 



For further information about Selecta and the company's partnering and collaboration opportunities, please contact bd@selectabio.com.

Link to press releases.

© 2016 Selecta Biosciences, Inc.  |  480 Arsenal St., Building One, Watertown, MA 02472  |  Phone: 617-923-1400  |   Fax: 617-924-3454  |  Email: info@selectabio.com
Privacy Policy  |  Web site designed and developed by RainCastle Communications, Inc.